Vicinitas Therapeutics is a biotechnology company focused on targeted protein stabilizers known as Deubiquituinase Targeting Chimeras (DUBTACs). The company’s mission is to use this proprietary technology to solve critical problems in human health by developing next-generation disease therapies against an entire class of previously inaccessible disease-causing proteins. The company spun out of technology that was developed through an academic-industry collaboration between UC Berkeley researchers and Novartis Institutes for BioMedical Research.
Dan Nomura